HEADER HYDROLASE 20-JUL-06 2HS1 TITLE ULTRA-HIGH RESOLUTION X-RAY CRYSTAL STRUCTURE OF HIV-1 PROTEASE V32I TITLE 2 MUTANT WITH TMC114 (DARUNAVIR) INHIBITOR COMPND MOL_ID: 1; COMPND 2 MOLECULE: HIV-1 PROTEASE; COMPND 3 CHAIN: A, B; COMPND 4 FRAGMENT: HIV-1 PROTEASE (RESIDUES 500-598); COMPND 5 EC: 3.4.23.16; COMPND 6 ENGINEERED: YES; COMPND 7 MUTATION: YES SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: HUMAN IMMUNODEFICIENCY VIRUS 1; SOURCE 3 ORGANISM_TAXID: 11676; SOURCE 4 GENE: GAG; SOURCE 5 EXPRESSION_SYSTEM: ESCHERICHIA COLI; SOURCE 6 EXPRESSION_SYSTEM_TAXID: 562 KEYWDS ULTRA-HIGH RESOLUTION ACTIVE SITE SURFACE BINDING SITE, HYDROLASE EXPDTA X-RAY DIFFRACTION AUTHOR I.T.WEBER,A.Y.KOVALEVSKY REVDAT 5 14-FEB-24 2HS1 1 REMARK REVDAT 4 20-OCT-21 2HS1 1 REMARK SEQADV HETSYN REVDAT 3 13-JUL-11 2HS1 1 VERSN REVDAT 2 24-FEB-09 2HS1 1 VERSN REVDAT 1 03-OCT-06 2HS1 0 JRNL AUTH A.Y.KOVALEVSKY,F.LIU,S.LESHCHENKO,A.K.GHOSH,J.M.LOUIS, JRNL AUTH 2 R.W.HARRISON,I.T.WEBER JRNL TITL ULTRA-HIGH RESOLUTION CRYSTAL STRUCTURE OF HIV-1 PROTEASE JRNL TITL 2 MUTANT REVEALS TWO BINDING SITES FOR CLINICAL INHIBITOR JRNL TITL 3 TMC114. JRNL REF J.MOL.BIOL. V. 363 161 2006 JRNL REFN ISSN 0022-2836 JRNL PMID 16962136 JRNL DOI 10.1016/J.JMB.2006.08.007 REMARK 2 REMARK 2 RESOLUTION. 0.84 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : SHELXL-97 REMARK 3 AUTHORS : G.M.SHELDRICK REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 0.84 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 20.00 REMARK 3 DATA CUTOFF (SIGMA(F)) : 0.000 REMARK 3 COMPLETENESS FOR RANGE (%) : 95.9 REMARK 3 CROSS-VALIDATION METHOD : FREE R REMARK 3 FREE R VALUE TEST SET SELECTION : RANDOM REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT (NO CUTOFF). REMARK 3 R VALUE (WORKING + TEST SET, NO CUTOFF) : 0.126 REMARK 3 R VALUE (WORKING SET, NO CUTOFF) : 0.124 REMARK 3 FREE R VALUE (NO CUTOFF) : 0.149 REMARK 3 FREE R VALUE TEST SET SIZE (%, NO CUTOFF) : 5.000 REMARK 3 FREE R VALUE TEST SET COUNT (NO CUTOFF) : 7689 REMARK 3 TOTAL NUMBER OF REFLECTIONS (NO CUTOFF) : 153847 REMARK 3 REMARK 3 FIT/AGREEMENT OF MODEL FOR DATA WITH F>4SIG(F). REMARK 3 R VALUE (WORKING + TEST SET, F>4SIG(F)) : 0.117 REMARK 3 R VALUE (WORKING SET, F>4SIG(F)) : 0.115 REMARK 3 FREE R VALUE (F>4SIG(F)) : 0.140 REMARK 3 FREE R VALUE TEST SET SIZE (%, F>4SIG(F)) : 5.000 REMARK 3 FREE R VALUE TEST SET COUNT (F>4SIG(F)) : 6558 REMARK 3 TOTAL NUMBER OF REFLECTIONS (F>4SIG(F)) : 131172 REMARK 3 REMARK 3 NUMBER OF NON-HYDROGEN ATOMS USED IN REFINEMENT. REMARK 3 PROTEIN ATOMS : 1514 REMARK 3 NUCLEIC ACID ATOMS : 0 REMARK 3 HETEROGEN ATOMS : 83 REMARK 3 SOLVENT ATOMS : 258 REMARK 3 REMARK 3 MODEL REFINEMENT. REMARK 3 OCCUPANCY SUM OF NON-HYDROGEN ATOMS : 1828.6 REMARK 3 OCCUPANCY SUM OF HYDROGEN ATOMS : 1681.2 REMARK 3 NUMBER OF DISCRETELY DISORDERED RESIDUES : 67 REMARK 3 NUMBER OF LEAST-SQUARES PARAMETERS : 20001 REMARK 3 NUMBER OF RESTRAINTS : 29807 REMARK 3 REMARK 3 RMS DEVIATIONS FROM RESTRAINT TARGET VALUES. REMARK 3 BOND LENGTHS (A) : 0.017 REMARK 3 ANGLE DISTANCES (A) : 0.039 REMARK 3 SIMILAR DISTANCES (NO TARGET VALUES) (A) : 0.000 REMARK 3 DISTANCES FROM RESTRAINT PLANES (A) : 0.035 REMARK 3 ZERO CHIRAL VOLUMES (A**3) : 0.102 REMARK 3 NON-ZERO CHIRAL VOLUMES (A**3) : 0.107 REMARK 3 ANTI-BUMPING DISTANCE RESTRAINTS (A) : 0.062 REMARK 3 RIGID-BOND ADP COMPONENTS (A**2) : 0.007 REMARK 3 SIMILAR ADP COMPONENTS (A**2) : 0.051 REMARK 3 APPROXIMATELY ISOTROPIC ADPS (A**2) : 0.111 REMARK 3 REMARK 3 BULK SOLVENT MODELING. REMARK 3 METHOD USED: NULL REMARK 3 REMARK 3 STEREOCHEMISTRY TARGET VALUES : ENGH AND HUBER REMARK 3 SPECIAL CASE: NULL REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: ANISOTROPIC REFINEMENT REDUCED FREE R REMARK 3 (NO CUTOFF) BY ? REMARK 4 REMARK 4 2HS1 COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY RCSB ON 01-AUG-06. REMARK 100 THE DEPOSITION ID IS D_1000038694. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : 12-JUL-05 REMARK 200 TEMPERATURE (KELVIN) : 90 REMARK 200 PH : 4.6 REMARK 200 NUMBER OF CRYSTALS USED : 1 REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : Y REMARK 200 RADIATION SOURCE : APS REMARK 200 BEAMLINE : 22-ID REMARK 200 X-RAY GENERATOR MODEL : NULL REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 0.8 REMARK 200 MONOCHROMATOR : NULL REMARK 200 OPTICS : NULL REMARK 200 REMARK 200 DETECTOR TYPE : CCD REMARK 200 DETECTOR MANUFACTURER : MARRESEARCH REMARK 200 INTENSITY-INTEGRATION SOFTWARE : HKL-2000 REMARK 200 DATA SCALING SOFTWARE : HKL-2000 REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 131172 REMARK 200 RESOLUTION RANGE HIGH (A) : 0.840 REMARK 200 RESOLUTION RANGE LOW (A) : 20.000 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : 2.000 REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 85.3 REMARK 200 DATA REDUNDANCY : NULL REMARK 200 R MERGE (I) : NULL REMARK 200 R SYM (I) : NULL REMARK 200 FOR THE DATA SET : NULL REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 0.84 REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : 0.87 REMARK 200 COMPLETENESS FOR SHELL (%) : 67.5 REMARK 200 DATA REDUNDANCY IN SHELL : NULL REMARK 200 R MERGE FOR SHELL (I) : NULL REMARK 200 R SYM FOR SHELL (I) : NULL REMARK 200 FOR SHELL : NULL REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: AB INITIO REMARK 200 SOFTWARE USED: SHELX REMARK 200 STARTING MODEL: NULL REMARK 200 REMARK 200 REMARK: NULL REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 39.51 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 2.03 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: 1-1.5 M NACL; MOLAR PROTEIN:INHIBITOR REMARK 280 RATIO = 1:20, PH 4.6, VAPOR DIFFUSION, HANGING DROP, TEMPERATURE REMARK 280 295K REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: P 21 21 21 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -X+1/2,-Y,Z+1/2 REMARK 290 3555 -X,Y+1/2,-Z+1/2 REMARK 290 4555 X+1/2,-Y+1/2,-Z REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -1.000000 0.000000 0.000000 14.35000 REMARK 290 SMTRY2 2 0.000000 -1.000000 0.000000 0.00000 REMARK 290 SMTRY3 2 0.000000 0.000000 1.000000 46.26700 REMARK 290 SMTRY1 3 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 3 0.000000 1.000000 0.000000 32.96150 REMARK 290 SMTRY3 3 0.000000 0.000000 -1.000000 46.26700 REMARK 290 SMTRY1 4 1.000000 0.000000 0.000000 14.35000 REMARK 290 SMTRY2 4 0.000000 -1.000000 0.000000 32.96150 REMARK 290 SMTRY3 4 0.000000 0.000000 -1.000000 0.00000 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 300 REMARK: THE ASYMMETRIC UNIT CONSISTS OF ONE HOMODIMER OF HIV-1 REMARK 300 PROTEASE MOLECULE (V32I MUTANT) COMPLEXED WITH CLINICAL INHIBITOR REMARK 300 TMC114 (DARUNAVIR). THE INHIBITOR OCCUPIES ACTIVE SITE CAVITY AND REMARK 300 ALSO BIND ON THE SURFACE OF THE PROTEIN. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: DIMERIC REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: DIMERIC REMARK 350 SOFTWARE USED: PISA,PQS REMARK 350 TOTAL BURIED SURFACE AREA: 5380 ANGSTROM**2 REMARK 350 SURFACE AREA OF THE COMPLEX: 10440 ANGSTROM**2 REMARK 350 CHANGE IN SOLVENT FREE ENERGY: -55.0 KCAL/MOL REMARK 350 APPLY THE FOLLOWING TO CHAINS: A, B REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: COVALENT BOND ANGLES REMARK 500 REMARK 500 THE STEREOCHEMICAL PARAMETERS OF THE FOLLOWING RESIDUES REMARK 500 HAVE VALUES WHICH DEVIATE FROM EXPECTED VALUES BY MORE REMARK 500 THAN 6*RMSD (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 500 IDENTIFIER; SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT: (10X,I3,1X,A3,1X,A1,I4,A1,3(1X,A4,2X),12X,F5.1) REMARK 500 REMARK 500 EXPECTED VALUES PROTEIN: ENGH AND HUBER, 1999 REMARK 500 EXPECTED VALUES NUCLEIC ACID: CLOWNEY ET AL 1996 REMARK 500 REMARK 500 M RES CSSEQI ATM1 ATM2 ATM3 REMARK 500 ARG A 8 NE - CZ - NH1 ANGL. DEV. = -3.2 DEGREES REMARK 500 LEU A 23 CA - CB - CG ANGL. DEV. = 21.4 DEGREES REMARK 500 ASP A 25 CB - CG - OD1 ANGL. DEV. = 6.3 DEGREES REMARK 500 ASP A 25 CB - CG - OD2 ANGL. DEV. = 5.5 DEGREES REMARK 500 ASP A 30 CB - CG - OD2 ANGL. DEV. = -7.3 DEGREES REMARK 500 MET A 36 CA - CB - CG ANGL. DEV. = 13.2 DEGREES REMARK 500 LYS A 55 CD - CE - NZ ANGL. DEV. = 19.3 DEGREES REMARK 500 TRP B 106 CE2 - CD2 - CG ANGL. DEV. = 4.9 DEGREES REMARK 500 TRP B 106 CE3 - CZ3 - CH2 ANGL. DEV. = 8.3 DEGREES REMARK 500 ARG B 108 NE - CZ - NH2 ANGL. DEV. = -4.1 DEGREES REMARK 500 ARG B 108 NE - CZ - NH2 ANGL. DEV. = -3.1 DEGREES REMARK 500 LEU B 123 CA - CB - CG ANGL. DEV. = 17.4 DEGREES REMARK 500 ASP B 125 CB - CG - OD2 ANGL. DEV. = -8.4 DEGREES REMARK 500 ASP B 130 CB - CG - OD1 ANGL. DEV. = 7.8 DEGREES REMARK 500 ARG B 141 NE - CZ - NH2 ANGL. DEV. = 4.0 DEGREES REMARK 500 MET B 146 CG - SD - CE ANGL. DEV. = 10.1 DEGREES REMARK 500 GLY B 149 C - N - CA ANGL. DEV. = -14.5 DEGREES REMARK 500 ASP B 160 CB - CG - OD1 ANGL. DEV. = 8.3 DEGREES REMARK 500 ASP B 160 CB - CG - OD2 ANGL. DEV. = -5.5 DEGREES REMARK 500 ILE B 163 CA - C - N ANGL. DEV. = 14.3 DEGREES REMARK 500 HIS B 169 CE1 - NE2 - CD2 ANGL. DEV. = 4.8 DEGREES REMARK 500 ASN B 198 OD1 - CG - ND2 ANGL. DEV. = 19.1 DEGREES REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 TRP A 42 143.51 168.25 REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: NON-CIS, NON-TRANS REMARK 500 REMARK 500 THE FOLLOWING PEPTIDE BONDS DEVIATE SIGNIFICANTLY FROM BOTH REMARK 500 CIS AND TRANS CONFORMATION. CIS BONDS, IF ANY, ARE LISTED REMARK 500 ON CISPEP RECORDS. TRANS IS DEFINED AS 180 +/- 30 AND REMARK 500 CIS IS DEFINED AS 0 +/- 30 DEGREES. REMARK 500 MODEL OMEGA REMARK 500 ARG A 41 TRP A 42 -145.07 REMARK 500 REMARK 500 REMARK: NULL REMARK 800 REMARK 800 SITE REMARK 800 SITE_IDENTIFIER: AC1 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE CL A 901 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC2 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE CL A 902 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC3 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE CL A 903 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC4 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE 017 A 201 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC5 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE 017 B 203 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC6 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE DMS B 204 DBREF 2HS1 A 1 99 UNP P03368 POL_HV1PV 500 598 DBREF 2HS1 B 101 199 UNP P03368 POL_HV1PV 500 598 SEQADV 2HS1 LYS A 7 UNP P03368 GLN 506 ENGINEERED MUTATION SEQADV 2HS1 ILE A 32 UNP P03368 VAL 531 ENGINEERED MUTATION SEQADV 2HS1 ILE A 33 UNP P03368 LEU 532 ENGINEERED MUTATION SEQADV 2HS1 ILE A 63 UNP P03368 LEU 562 ENGINEERED MUTATION SEQADV 2HS1 ALA A 67 UNP P03368 CYS 566 ENGINEERED MUTATION SEQADV 2HS1 ALA A 95 UNP P03368 CYS 594 ENGINEERED MUTATION SEQADV 2HS1 LYS B 107 UNP P03368 GLN 506 ENGINEERED MUTATION SEQADV 2HS1 ILE B 132 UNP P03368 VAL 531 ENGINEERED MUTATION SEQADV 2HS1 ILE B 133 UNP P03368 LEU 532 ENGINEERED MUTATION SEQADV 2HS1 ILE B 163 UNP P03368 LEU 562 ENGINEERED MUTATION SEQADV 2HS1 ALA B 167 UNP P03368 CYS 566 ENGINEERED MUTATION SEQADV 2HS1 ALA B 195 UNP P03368 CYS 594 ENGINEERED MUTATION SEQRES 1 A 99 PRO GLN ILE THR LEU TRP LYS ARG PRO LEU VAL THR ILE SEQRES 2 A 99 LYS ILE GLY GLY GLN LEU LYS GLU ALA LEU LEU ASP THR SEQRES 3 A 99 GLY ALA ASP ASP THR ILE ILE GLU GLU MET SER LEU PRO SEQRES 4 A 99 GLY ARG TRP LYS PRO LYS MET ILE GLY GLY ILE GLY GLY SEQRES 5 A 99 PHE ILE LYS VAL ARG GLN TYR ASP GLN ILE ILE ILE GLU SEQRES 6 A 99 ILE ALA GLY HIS LYS ALA ILE GLY THR VAL LEU VAL GLY SEQRES 7 A 99 PRO THR PRO VAL ASN ILE ILE GLY ARG ASN LEU LEU THR SEQRES 8 A 99 GLN ILE GLY ALA THR LEU ASN PHE SEQRES 1 B 99 PRO GLN ILE THR LEU TRP LYS ARG PRO LEU VAL THR ILE SEQRES 2 B 99 LYS ILE GLY GLY GLN LEU LYS GLU ALA LEU LEU ASP THR SEQRES 3 B 99 GLY ALA ASP ASP THR ILE ILE GLU GLU MET SER LEU PRO SEQRES 4 B 99 GLY ARG TRP LYS PRO LYS MET ILE GLY GLY ILE GLY GLY SEQRES 5 B 99 PHE ILE LYS VAL ARG GLN TYR ASP GLN ILE ILE ILE GLU SEQRES 6 B 99 ILE ALA GLY HIS LYS ALA ILE GLY THR VAL LEU VAL GLY SEQRES 7 B 99 PRO THR PRO VAL ASN ILE ILE GLY ARG ASN LEU LEU THR SEQRES 8 B 99 GLN ILE GLY ALA THR LEU ASN PHE HET CL A 901 1 HET CL A 902 1 HET CL A 903 1 HET 017 A 201 76 HET 017 B 203 38 HET DMS B 204 4 HETNAM CL CHLORIDE ION HETNAM 017 (3R,3AS,6AR)-HEXAHYDROFURO[2,3-B]FURAN-3-YL(1S,2R)-3- HETNAM 2 017 [[(4-AMINOPHENYL)SULFONYL](ISOBUTYL)AMINO]-1-BENZYL-2- HETNAM 3 017 HYDROXYPROPYLCARBAMATE HETNAM DMS DIMETHYL SULFOXIDE HETSYN 017 DARUNAVIR; TMC114; UIC-94017 FORMUL 3 CL 3(CL 1-) FORMUL 6 017 2(C27 H37 N3 O7 S) FORMUL 8 DMS C2 H6 O S FORMUL 9 HOH *258(H2 O) HELIX 1 1 GLY A 86 THR A 91 1 6 HELIX 2 2 GLY B 186 THR B 191 1 6 HELIX 3 3 GLN B 192 GLY B 194 5 3 SHEET 1 A 4 GLN A 2 ILE A 3 0 SHEET 2 A 4 THR B 196 ASN B 198 -1 O LEU B 197 N ILE A 3 SHEET 3 A 4 THR A 96 ASN A 98 -1 N ASN A 98 O THR B 196 SHEET 4 A 4 GLN B 102 ILE B 103 -1 O ILE B 103 N LEU A 97 SHEET 1 B 8 LYS A 43 GLY A 49 0 SHEET 2 B 8 GLY A 52 ILE A 66 -1 O VAL A 56 N LYS A 45 SHEET 3 B 8 HIS A 69 VAL A 77 -1 O HIS A 69 N ILE A 66 SHEET 4 B 8 THR A 31 ILE A 33 1 N ILE A 33 O LEU A 76 SHEET 5 B 8 ILE A 84 ILE A 85 -1 O ILE A 84 N ILE A 32 SHEET 6 B 8 GLN A 18 LEU A 24 1 N LEU A 23 O ILE A 85 SHEET 7 B 8 LEU A 10 ILE A 15 -1 N VAL A 11 O ALA A 22 SHEET 8 B 8 GLY A 52 ILE A 66 -1 O GLU A 65 N LYS A 14 SHEET 1 C 8 LYS B 143 GLY B 149 0 SHEET 2 C 8 GLY B 152 ILE B 166 -1 O GLN B 158 N LYS B 143 SHEET 3 C 8 HIS B 169 VAL B 177 -1 O HIS B 169 N ILE B 166 SHEET 4 C 8 ILE B 132 ILE B 133 1 N ILE B 133 O LEU B 176 SHEET 5 C 8 ILE B 184 ILE B 185 -1 O ILE B 184 N ILE B 132 SHEET 6 C 8 GLN B 118 LEU B 124 1 N LEU B 123 O ILE B 185 SHEET 7 C 8 LEU B 110 ILE B 115 -1 N ILE B 113 O LYS B 120 SHEET 8 C 8 GLY B 152 ILE B 166 -1 O GLU B 165 N LYS B 114 SITE 1 AC1 4 VAL A 11 THR A 12 HOH A1253 LYS B 107 SITE 1 AC2 4 LYS A 7 VAL B 111 THR B 112 HOH B1056 SITE 1 AC3 3 LEU A 38 GLY A 40 LYS B 155 SITE 1 AC4 29 ARG A 8 ASP A 25 GLY A 27 ALA A 28 SITE 2 AC4 29 ASP A 29 ASP A 30 GLY A 48 GLY A 49 SITE 3 AC4 29 ILE A 50 PRO A 81 VAL A 82 ILE A 84 SITE 4 AC4 29 HOH A1001 HOH A1005 HOH A1006 HOH A1224 SITE 5 AC4 29 ARG B 108 ASP B 125 GLY B 127 ALA B 128 SITE 6 AC4 29 ASP B 129 ASP B 130 ILE B 132 GLY B 148 SITE 7 AC4 29 GLY B 149 ILE B 150 PRO B 181 VAL B 182 SITE 8 AC4 29 HOH B1002 SITE 1 AC5 21 TRP A 6 GLY A 40 ARG A 41 GLU B 135 SITE 2 AC5 21 PRO B 144 LYS B 145 LYS B 155 VAL B 156 SITE 3 AC5 21 ARG B 157 GLY B 168 VAL B 177 GLY B 178 SITE 4 AC5 21 GLN B 192 GLY B 194 HOH B1023 HOH B1051 SITE 5 AC5 21 HOH B1074 HOH B1086 HOH B1098 HOH B1143 SITE 6 AC5 21 HOH B1254 SITE 1 AC6 5 TRP A 6 TRP B 142 ARG B 157 HOH B1023 SITE 2 AC6 5 HOH B1074 CRYST1 28.700 65.923 92.534 90.00 90.00 90.00 P 21 21 21 8 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.034843 0.000000 0.000000 0.00000 SCALE2 0.000000 0.015169 0.000000 0.00000 SCALE3 0.000000 0.000000 0.010807 0.00000